1月19日晚间，江阴江化微电子材料股份有限公司（以下简称"江化微"）发布公告，公司控股股东淄博 星恒途松控股有限公司（以下简称"淄博星恒途松"）筹划重大事项已取得进一步进展，公司股票自1月 20日起复牌。 （文章来源：证券日报） 对于此次股权转让的原因，江化微公司提及，上海福迅科技基于对上市公司中长期内在价值及所处产业 发展前景的认可，拟通过本次权益变动成为上市公司的控股股东并取得上市公司的控制权。本次权益变 动完成后，上海福迅科技将充分发挥产业协同，为上市公司业务发展赋能，按照有利于上市公司可持续 发展、有利于全体股东权益的原则，进一步增强上市公司产业竞争力与盈利能力，提升上市公司价值。 公告显示，本次拟转让股份每股价格为20元，转让总价款约为18.48亿元。 上海明伦律师事务所王智斌律师告诉《证券日报》记者，控制权的变更容易引发二级市场的股价异动， 因此，上市公司在这个过程中，要注意信息披露的及时、公正，保证所有投资者的知情权，在股价异动 时，也要及时分析原因并对外披露信息，以更好地保护中小投资者的合法权益。 "上市公司控制权变更后，随着新股东的进入，战略方向、资源配置、资金链稳定性上将获得更多支 持，有 ...

Group 1 - The core point of the news is that Jiangyin Jianghua Microelectronics Co., Ltd. is undergoing a significant change in its controlling shareholder, moving from Zibo Xingheng Tusheng Holdings to Shanghai Fuxun Technology Co., Ltd. [1] - The share transfer agreement has been signed, and the transaction price is approximately 1.848 billion yuan, with a per-share price of 20 yuan [2]. - The new controlling shareholder, Shanghai Fuxun Technology, recognizes the long-term intrinsic value of the company and aims to enhance its competitiveness and profitability through industrial synergy [1][2]. Group 2 - The change in control is expected to lead to strategic support in resource allocation and funding stability, which may benefit research and development investments and capacity expansion [2]. - The company is advised to ensure timely and fair information disclosure during the control change process to protect the rights of all investors [2].

另外，公司拟以5.06元/股的价格，向北京融晟致瑞科技发展合伙企业（有限合伙）（简称"融晟致瑞"）发行股票5000万股，募资不超过2.53亿元，用于偿 还银行借款或补充流动资金。发行完成后，按照拟发行股数计算，融晟致瑞持股比例为13.3%。 通过上述交易，融晟致瑞成为公司控股股东，融晟鑫泰为融晟致瑞的一致行动人，融晟致瑞及融晟鑫泰的实控人尉立东成为公司实控人。 然而，这场资本运作却在董事会层面引发分歧，天晟新材昔日第一大股东青岛融海国投资产管理有限公司（下称"融海国投"）委派董事韩庆军对方案连续 投出25张反对票，引发市场关注。 新实控人毕业于清华大学 1月14日，天晟新材股东孙剑、吕泽伟与北京融晟鑫泰科技发展合伙企业（有限合伙）（简称"融晟鑫泰"）签署《股份转让协议》，约定融晟鑫泰合计受 让孙剑、吕泽伟持有的公司2048.95万股股份，转让价格6.39元/股。协议转让完成后，融晟鑫泰持有公司6.29%股份。 公告显示，融晟鑫泰成立于2026年1月6日，注册资金1.9亿元，本次权益变动的资金全部来源于自有资金及自筹资金。 新东家尉立东是何许人也，公告显示，出生于1975年的尉立东，毕业于清华大学，获得工学学士 ...

Core Viewpoint - Shimao Energy's stock experienced a significant drop of 9.99% to 31.46 yuan per share following the announcement of the termination of its control rights change plan, highlighting the volatility in stock prices associated with such corporate events [3][8]. Group 1: Control Rights Change Termination - On January 16, Shimao Energy announced the termination of its control rights change plan due to a lack of agreement on key terms between its controlling shareholder and the transaction counterparties [4][5]. - The termination occurred just five days after the announcement of the planned share transfer, indicating rapid developments in the negotiations [5]. - Key terms typically involved in control rights changes include share transfer pricing, approval processes, performance commitments, voting rights handling, funding sources, transitional arrangements, and liability for breaches [6]. Group 2: Market Reaction and Historical Context - Following the resumption of trading on January 19, Shimao Energy's stock hit the daily limit down, reflecting market reactions to the abrupt termination of the control rights change [8]. - Prior to the suspension, the stock had seen a significant increase of over 19% in just two trading days, illustrating the impact of market sentiment on stock performance [8]. - This is not the first instance of Shimao Energy facing challenges in capital operations; a previous attempt to acquire a stake in Nantong Zhanding Material Technology was also terminated due to disagreements on transaction conditions [9]. Group 3: Governance and Disclosure Concerns - Analysts suggest that the lack of transparency regarding the transaction counterparties and their development plans raises questions about the rigor of Shimao Energy's decision-making processes [10]. - The repeated initiation of significant corporate actions without thorough justification and transparent disclosure may undermine investor confidence in the company's governance and strategic execution [11]. - The China Securities Regulatory Commission has emphasized the importance of enhancing transaction and information disclosure regulations to maintain market fairness and prevent excessive volatility [11].

据梳理，1月份以来，江阴江化微电子材料股份有限公司、浙江华是科技股份有限公司、常州天晟新材料集团股份有限公 司、阳光新业地产股份有限公司等上市公司皆发布了有关"筹划控制权变更事项停牌"的公告。 刘有华告诉记者，上市公司控制权变更，受政策、产业与资本三方面因素驱动。政策层面，"并购六条"等举措优化监管流 程、提升审核效率，释放制度红利；产业层面，企业转型升级需求迫切，通过控制权整合产业链或切入新兴赛道；资金层面， 国资与产业资本积极布局，为优质标的提供支持。此外，部分企业也借此引入新股东以突破经营或融资瓶颈，实现可持续发 展。 本报记者 桂小笋 进入2026年以来，陆续有上市公司发布公告，筹划控制权变更的相关事项。据《证券日报》记者统计，截至1月13日，今 年已有13家上市公司发布了控制权变更的相关公告。 梳理公告内容来看，控股股东及实际控制人筹划转让上市公司股权，是这些上市公司控制权可能发生变更的主要原因。 接受《证券日报》记者采访的行业人士表示，出现这种现象，是资本市场优化资源配置的积极信号。 深圳市前海排排网基金销售有限责任公司研究总监刘有华告诉《证券日报》记者："这一现象契合当前产业升级与经济结 构转型 ...

Core Viewpoint - Nanjing Aolian Automotive Electronics Co., Ltd. announced a temporary suspension of trading due to plans for a change in control, following a notification from its controlling shareholder, Guangxi Ruiying Asset Management Co., Ltd. [1][3] Group 1: Company Announcement - On December 22, Aolian Electronics announced a temporary suspension of its stock trading to disclose significant matters [1][3] - The reason for the suspension was the notification received on December 19 from its controlling shareholder regarding the planning of a transfer of part of its shares, which may lead to a change in the controlling shareholder and actual controller [1][3] - The company expects the suspension to last no more than two trading days [1][3] Group 2: Legal and Market Implications - According to legal experts, there are five common scenarios for changes in control of listed companies, with agreement transfer being the most common [2][4] - Changes in control can attract investor attention, necessitating compliance and consideration of the sustainability of the main business post-change [2][4] - The process of planning a change in control requires timely and accurate disclosure of information to prevent insider trading and market manipulation [2][4] Group 3: Industry Context - The change in control may be a strategic choice for companies facing performance pressure, allowing for the introduction of new stakeholders to facilitate transformation [2][4] - Different backgrounds of shareholders can assist in achieving industry chain integration, strategic investment, or resource optimization [2][4] - The effectiveness of the control change in revitalizing the company will depend on actual progress in industry collaboration and resource integration [2][4] - Aolian Electronics specializes in automotive parts manufacturing, with products related to power electronics control, body electronics control, and new energy system control [2][4] - The company recently completed a board restructuring in November [2][4]

Group 1 - The core point of the news is that Nanjing Aolian Automotive Electronics Co., Ltd. announced a temporary suspension of trading due to a potential change in control, as the controlling shareholder, Guangxi Ruiying Asset Management Co., Ltd., is planning to transfer part of its shares [1] - The company has applied for a trading suspension starting from December 22, with an expected duration of no more than two trading days [1] - Legal experts indicate that changes in control of listed companies can occur through various means, with agreement transfer being the most common method [1] Group 2 - The change in control may provide opportunities for companies facing performance pressures to introduce new shareholders for transformation [2] - The effectiveness of the control change in revitalizing the company will depend on actual outcomes in terms of industrial collaboration and resource optimization [2] - Aolian Electronics specializes in automotive components, including power electronics control and body electronics control, and recently completed a board restructuring in November [2]

Core Viewpoint - The announcement details the change of control at Henan Tailong Pharmaceutical Co., Ltd., with the transfer of shares from the current controlling shareholder to Jiang Pharmaceutical Group Jiangxi Pharmaceutical Holdings Co., Ltd. This transaction includes a share transfer agreement, a concerted action agreement, and a conditional share subscription agreement. Group 1: Share Transfer Details - On December 8, 2025, the controlling shareholder Zhengzhou Tai Rong Industrial Investment Co., Ltd. agreed to transfer 50,100,000 shares (8.73% of total shares) to Jiang Pharmaceutical Holdings at a price of 11.043 CNY per share, totaling 553,254,300 CNY [2][4] - The share transfer will occur in two phases: the first phase involves 42,300,000 shares (7.37% of total shares) and the second phase involves 7,800,000 shares (1.36% of total shares) [3][4] Group 2: Concerted Action Agreement - A concerted action agreement was signed on December 8, 2025, stipulating that Tai Rong and Jiang Pharmaceutical Holdings will make joint decisions on major company matters, with Jiang Pharmaceutical Holdings having the final say in case of disagreements [3][4] Group 3: New Share Issuance - Jiang Pharmaceutical Holdings plans to fully subscribe to a new issuance of up to 74,605,216 shares, which would represent 19.23% of the total shares post-issuance, subject to regulatory approvals [4][9] - The issuance price is set at 6.09 CNY per share, which is not less than 80% of the average trading price over the previous 20 trading days [9][10] Group 4: Control Change and Governance - The controlling shareholder will change from Tai Rong to Jiang Pharmaceutical Holdings, with the actual controller shifting from Zhengzhou High-tech Industrial Development Zone Management Committee to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [4][12] - The governance structure will be adjusted to reflect the new ownership, with Jiang Pharmaceutical Holdings entitled to nominate a significant number of board members [35][36] Group 5: Financial and Operational Impact - The transaction is expected to enhance the company's strategic development in traditional Chinese medicine and health sectors, leveraging Jiang Pharmaceutical's resources [7] - The company assures that the transaction will not adversely affect its normal operations [6]

Core Viewpoint - The share transfer agreement between Mr. Lu Nan, the largest shareholder of Sichuan Medical Technology Co., Ltd. (300078.SZ), and Cangnan Construction Investment Co., Ltd. has been terminated due to the lack of approval from relevant state-owned asset supervision authorities [1][2] Group 1 - Mr. Lu Nan intends to transfer 62,739,500 shares, representing 5.61% of the company's total share capital, to Cangnan Construction Investment [1] - After the transfer, Cangnan Construction Investment will hold 62,739,500 shares, and together with Cangnan Sijia Internet of Things Intelligent Partnership, they will control 11.33% of the company's total shares [1] - The control of the company will shift from Mr. Lu Nan and his action-in-concert party to Cangnan Construction Investment and its action-in-concert party, indicating a change in the company's actual controller to the Cangnan County Finance Bureau [1] Group 2 - The Zhejiang Provincial State-owned Assets Supervision and Administration Commission returned the application materials for the acquisition of control over Sichuan Medical Technology, stating that the proposal did not meet regulatory requirements [2] - Following the return of the application, Cangnan Construction Investment issued a notice to terminate the share transfer agreement, as the lack of approval triggered a clause allowing for termination without liability [2] - Both parties agreed to terminate the share transfer to protect their interests and avoid unnecessary losses [2]

Core Viewpoint - The announcement from Haocen Medical indicates a change in control due to the termination of a cooperation agreement between Huyin Aofeng and Beijing Shoutuo Ronghui, resulting in no actual controller for the listed company [1] Group 1 - Huyin Aofeng, through Huyin Rifeng, indirectly controls 23.81% of the voting rights of the listed company [1] - Huyin Aofeng's shareholders have balanced shareholding ratios and no concerted action arrangements, leading to the absence of an actual controller [1] - The change in equity will not adversely affect the normal production and operation of the company [1]